Nemaura Medical to Present at the Maxim Group Emerging Growth in A.I. Conference
September 18 2023 - 9:15AM
Nemaura Medical, Inc. (NASDAQ: NMRD), a medical technology company
focused on developing and commercializing non-invasive wearable
diagnostic devices and supporting personalized lifestyle coaching
programs, announces today that CEO Dr. Faz Chowdhury will present
business updates and developments at the Maxim Group Emerging
Growth in A.I., virtual conference.
The presentation will take place at 11am Eastern time on 27
September 2023.
Register for the conference here: www.m-vest.com
About Nemaura Medical, Inc.
Nemaura Medical Inc. is a medical technology
company developing and commercialising non-invasive wearable
diagnostic devices. The Company is currently also commercialising
sugarBEAT® and proBEAT™. sugarBEAT®, a CE mark approved Class
IIb medical device, is a non-invasive and flexible continuous
glucose monitor (CGM) providing actionable insights derived from
real time glucose measurements and daily glucose trend data, which
may help people with diabetes and prediabetes to better manage,
reverse, and prevent the onset of diabetes. Nemaura has submitted a
PMA (Premarket Approval Application) for sugarBEAT® to the
U.S. Food and Drug Administration (the “FDA”).
proBEAT™ combines non-invasive glucose data processed using
artificial intelligence as part of a lifestyle program that is
being refined for commercial launch.
The Company sits at the intersection of the
global Type 2 diabetes market that is expected to reach nearly $59
billion by 2025, the $50+ billion pre-diabetic market, and the
wearable health-tech sector for weight loss and wellness
applications that is estimated to reach $60 billion by 2023.
For more information, please
visit www.NemauraMedical.com.
Cautionary Statement Regarding Forward-Looking
Statements:
The statements in this press release that are
not historical facts may constitute forward-looking statements that
are based on current expectations and are subject to risks and
uncertainties that could cause actual future results to differ
materially from those expressed or implied by such statements.
Those risks and uncertainties include, but are not limited to, the
launch of proBEAT™ in the U.S., risks related to regulatory
status and the failure of future development and preliminary
marketing efforts, Nemaura’s ability to secure additional
commercial partnering arrangements, risks and uncertainties
relating to Nemaura’s and its partners’ ability to develop, market
and sell proBEAT™, the availability of substantial additional
equity or debt capital to support its research, development and
product commercialization activities, and the success of its
research, development, regulatory approval, marketing and
distribution plans and strategies, including those plans and
strategies related to both proBEAT™ digital health, and
sugarBEAT®. There can be no assurance that the Company will be able
to reach a part of or any of the global market for CGM with its
products/services. The FDA reserves the right to re-evaluate its
decision that proBEAT™ qualifies as a general wellness product
should it become aware of any issues such as skin irritation or
other adverse events from the device, as well as any misuse
impacting patient safety, and any other reason as the FDA may see
fit at its discretion to determine the product does not fit the
definition of a general wellness product. These and other risks and
uncertainties are identified and described in more detail in
Nemaura’s filings with the United States Securities and Exchange
Commission, including, without limitation, its Annual Report on
Form 10-K for the most recently completed fiscal year, its
Quarterly Reports on Form 10-Q, and its Current Reports on Form
8-K, as the same may be amended from time to time. Nemaura
undertakes no obligation to publicly update or revise any
forward-looking statements.
Investor
Relations:IR@NemauraMedical.Com
Nemaura Medical (NASDAQ:NMRD)
Historical Stock Chart
From Jun 2024 to Jul 2024
Nemaura Medical (NASDAQ:NMRD)
Historical Stock Chart
From Jul 2023 to Jul 2024